相关临床试验
78
7 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1964
进行中（未招募）
3
3.9%
已完成
52
66.7%
Enrolling By Invitation
1
1.3%
尚未招募
3
3.9%
招募中
14
17.9%
终止
2
2.6%
撤回
3
3.9%
暂无批准数据
- ZEO ScientifiX announced plans to expand its regenerative biologics and provider-support operations into Georgia and Tennessee following enactment of new state regenerative medicine laws. - Georgia House Bill 1275 was signed on May 11, 2026, and Tennessee House Bill 2246 on May 19, 2026, establishing state-level frameworks for qualifying therapies. - Tennessee's framework expressly includes certain exosome-based regenerative products within its definition of regenerative medicine therapy when statutory product and manufacturing criteria are met. - The company states the state laws do not constitute FDA approval and do not displace federal law, leaving providers responsible for compliance with all applicable requirements.
- Inflammasome Therapeutics has been selected as one of the first companies to participate in the Healey ALS MyMatch program, collaborating with Massachusetts General Hospital to test oral Kamuvudine-9 (K9) in ALS patients. - Preclinical studies show K9 reduces neurofilament light chain levels by 80% or more in human ALS motor neurons and animal models, a biomarker that is prognostic of disease progression. - The multi-inflammasome inhibitor K9 targets neuroinflammation, a disease process characterizing ALS and other neurodegenerative conditions, with potential to treat the 95% of ALS patients who don't qualify for existing targeted therapies. - The Healey ALS MyMatch program uses biomarker-driven personalized trial approaches to match ALS patient subgroups to experimental therapies based on their disease markers in Phase 1b/2a trials.
- ZEO ScientifiX announces readiness to capitalize on Florida's new stem cell law SB 1768, which authorizes licensed physicians to administer non-FDA-approved stem cell therapies for orthopedic, wound care, and pain management indications. - The legislation enables the company to collect real-world safety and outcome data from providers, potentially reducing risks for future FDA submissions and accelerating clinical trial objectives at reduced costs. - ZEO has launched an IRB-approved clinical study for its PPX therapy targeting musculoskeletal joint pathologies, planning to enroll up to 350 patients across participating clinics. - The company is evaluating expansion of its laboratory facilities at Nova Southeastern University to support growth in intellectual property portfolio and increase product and clinical trial capacity.
- Three prominent clinical trials testing Paxlovid and monoclonal antibodies for Long COVID failed to show significant health improvements compared to placebo groups. - The trials were designed as "proof of concept" studies to test viral persistence theory, with researchers acknowledging they expected challenging results but hoped for better outcomes. - Future trials are being designed with longer treatment durations, larger patient populations, and more specific biomarkers to better target viral persistence in Long COVID patients. - New monoclonal antibody trials are underway, including sipavibart at Nova Southeastern University and planned studies with Pemgarda, which may offer longer-lasting effects than short-course antivirals.
- Nova Southeastern University researchers have begun a clinical trial testing AstraZeneca's monoclonal antibody sipavibart as a potential treatment for Long COVID, funded by the Schmidt Initiative for Long COVID. - The double-blind, randomized controlled trial will enroll 100 patients to evaluate whether sipavibart, already approved for COVID-19 prevention in Japan and the EU, can improve cognitive dysfunction, autonomic nervous system effects, and exercise tolerance. - This trial is one of three Long COVID treatment studies launching in 2025, alongside another global study testing anti-inflammatory drugs upadacitinib and pirfenidone across seven locations on four continents.
